TSPO-PET in conjunction with tau- and/or Aβ-PET in cohorts of AD and primary tauopathy patients (i.e., progressive supranuclear palsy or corticobasal degeneration) would translate our present findings into the study of human disease. Here, MAPT is linked to Classical progressive supranuclear palsy.